CN107074968B - 疫苗 - Google Patents

疫苗 Download PDF

Info

Publication number
CN107074968B
CN107074968B CN201580046960.4A CN201580046960A CN107074968B CN 107074968 B CN107074968 B CN 107074968B CN 201580046960 A CN201580046960 A CN 201580046960A CN 107074968 B CN107074968 B CN 107074968B
Authority
CN
China
Prior art keywords
denv
gly
ediii
leu
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580046960.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN107074968A (zh
Inventor
纳温·康纳
维斯瓦纳坦·拉玛沙米
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International Centre for Genetic Engineering and Biotechnology
Original Assignee
International Centre for Genetic Engineering and Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by International Centre for Genetic Engineering and Biotechnology filed Critical International Centre for Genetic Engineering and Biotechnology
Publication of CN107074968A publication Critical patent/CN107074968A/zh
Application granted granted Critical
Publication of CN107074968B publication Critical patent/CN107074968B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Cartons (AREA)
  • Packaging Of Annular Or Rod-Shaped Articles, Wearing Apparel, Cassettes, Or The Like (AREA)
CN201580046960.4A 2014-09-01 2015-08-21 疫苗 Active CN107074968B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2478DE2014 2014-09-01
IN2478/DEL/2014 2014-09-01
PCT/IB2015/056352 WO2016034974A1 (en) 2014-09-01 2015-08-21 Vaccine

Publications (2)

Publication Number Publication Date
CN107074968A CN107074968A (zh) 2017-08-18
CN107074968B true CN107074968B (zh) 2021-03-12

Family

ID=55439184

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580046960.4A Active CN107074968B (zh) 2014-09-01 2015-08-21 疫苗

Country Status (19)

Country Link
US (3) US10189877B2 (enExample)
EP (2) EP3188755B1 (enExample)
JP (3) JP6983653B2 (enExample)
CN (1) CN107074968B (enExample)
BR (1) BR112017004008A2 (enExample)
CA (1) CA2959280C (enExample)
CY (1) CY1123664T1 (enExample)
ES (1) ES2821480T3 (enExample)
HR (1) HRP20201523T1 (enExample)
HU (1) HUE053284T2 (enExample)
LT (1) LT3188755T (enExample)
MX (2) MX385222B (enExample)
MY (1) MY201688A (enExample)
PL (1) PL3188755T3 (enExample)
PT (1) PT3188755T (enExample)
RS (1) RS61000B1 (enExample)
SI (1) SI3188755T1 (enExample)
SM (1) SMT202000589T1 (enExample)
WO (1) WO2016034974A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202000589T1 (it) * 2014-09-01 2020-11-10 Int Centre For Genetic Engineering And Biotechnology Vaccino
US11793873B2 (en) 2017-05-10 2023-10-24 University Of Massachusetts Bivalent dengue/hepatitis B vaccines

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766205A (en) * 1985-11-13 1988-08-23 Beatrice Companies, Inc. Method for isolation of recombinant polypeptides in biologically active forms
AU2927892A (en) 1991-11-16 1993-06-15 Smithkline Beecham Biologicals (Sa) Hybrid protein between cs from plasmodium and hbsag
FR2741077B1 (fr) * 1995-11-14 1998-01-23 Pasteur Institut Vaccin polyvalent anti-dengue
WO2007034507A2 (en) * 2005-09-20 2007-03-29 International Centre For Genetic Engineering And Biotechnology Tetravalent dengue specific domain iii based chimeric recombinant protein
WO2008152652A2 (en) * 2007-06-12 2008-12-18 International Centre For Genetic Engineering And Biotechnology A dengue envelope domain iii-based tetravalent protein vaccine
WO2010043977A2 (en) * 2008-10-13 2010-04-22 Institute For Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
CN101962411B (zh) * 2009-07-24 2012-09-05 中国疾病预防控制中心病毒病预防控制所 登革病毒血清学早期诊断试剂
MX2012012681A (es) * 2010-05-21 2012-12-17 Univ Pittsburgh Secuencias del virus de dengue universales y metodos de uso.
CN103193870B (zh) * 2013-04-22 2014-10-22 中国人民解放军第三军医大学 一种登革病毒简并疫苗及其应用
SMT202000589T1 (it) * 2014-09-01 2020-11-10 Int Centre For Genetic Engineering And Biotechnology Vaccino

Also Published As

Publication number Publication date
JP6983653B2 (ja) 2021-12-17
JP6985458B2 (ja) 2021-12-22
BR112017004008A2 (pt) 2018-01-23
US10815280B2 (en) 2020-10-27
MY201688A (en) 2024-03-13
EP3188755A1 (en) 2017-07-12
MX385222B (es) 2025-03-14
JP7333373B2 (ja) 2023-08-24
CA2959280A1 (en) 2016-03-10
US20170240601A1 (en) 2017-08-24
RS61000B1 (sr) 2020-11-30
JP2022031791A (ja) 2022-02-22
HUE053284T2 (hu) 2021-06-28
CN107074968A (zh) 2017-08-18
US11945842B2 (en) 2024-04-02
EP3685852A1 (en) 2020-07-29
MX2021006543A (es) 2021-10-13
US10189877B2 (en) 2019-01-29
LT3188755T (lt) 2020-12-28
EP3188755B1 (en) 2020-08-05
MX2017002621A (es) 2017-07-28
CY1123664T1 (el) 2022-03-24
WO2016034974A1 (en) 2016-03-10
JP2017526366A (ja) 2017-09-14
PL3188755T3 (pl) 2021-01-25
CA2959280C (en) 2023-09-26
PT3188755T (pt) 2020-09-29
ES2821480T3 (es) 2021-04-26
US20210122787A1 (en) 2021-04-29
HRP20201523T1 (hr) 2021-03-05
SI3188755T1 (sl) 2021-03-31
SMT202000589T1 (it) 2020-11-10
US20190194261A1 (en) 2019-06-27
JP2020162611A (ja) 2020-10-08

Similar Documents

Publication Publication Date Title
Tripathi et al. Recent developments in recombinant protein–based dengue vaccines
Mani et al. Pichia pastoris-expressed dengue 2 envelope forms virus-like particles without pre-membrane protein and induces high titer neutralizing antibodies
US11926648B2 (en) Neutralising antibody against dengue for use in a method of prevention and/or treatment of Zika infection
Etemad et al. An envelope domain III–based chimeric antigen produced in pichia pastoris elicits Neutralizing antibodies against all four dengue virus serotypes
JP2025172747A (ja) 抗デング熱ワクチン及び抗体
Chua et al. A novel platform for virus-like particle-display of flaviviral envelope domain III: induction of Dengue and West Nile virus neutralizing antibodies
EP2959915A1 (en) A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection
Zhang et al. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection
CN110551187A (zh) 化学合成的h7n9禽流感病毒na蛋白胞外区抗原片段及制备方法和应用
Batra et al. Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neutralizing antibodies
JP7333373B2 (ja) ワクチン
Zhang et al. The Leu477 and Leu613 of ORF2-encoded protein are critical in forming neutralization antigenic epitope of hepatitis E virus genotype 4
CN112812193A (zh) 诺如病毒gii.4型和肠道病毒71型的重组蛋白疫苗
JP4417712B2 (ja) ウイルスに対する作用を誘導するタンパク質をコードするキメラ鎖
CN112823021A (zh) 稳定化的丝状病毒糖蛋白三聚体
HK40032428A (en) Vaccine
Zhang et al. A shared N-terminal hydrophobic tail for the formation of nanoparticulates
Rathore et al. Production and immunogenicity of Fubc subunit protein redesigned from DENV envelope protein
US10772949B2 (en) Dengue virus glycoprotein E DIII variants and uses thereof
Choe Structure-based antiviral drug discovery
Shrestha Recombinant viral particle protein expression against dengue virus serotype-1
Panapitakkul Stimulation of immune response in mice using the plant-produced SARS-CoV-2 S1 subunit protein linked to the fc region
US20220372079A1 (en) Resurfaced dengue virus and ziki virus glycoprotein e diii variants and uses thereof
WO2025146159A1 (zh) 针对寨卡/登革病毒的重组抗原、其疫苗组合物及其应用
BR112017001340B1 (pt) Epítopo de dímero e, composição, composição farmacêutica, kit, método para a síntese do ede e para produzir um anticorpo ou porção de ligação ao antígeno do mesmo, método in vitro para monitorar a progressão ou regressão de uma infecção por vírus da dengue ou prever a evolução no tempo da mesma, para diagnosticar uma infecção por vírus da dengue e para monitorar o sucesso de um protocolo de vacinação contra uma infecção de vírus da dengue e usos dos mesmos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant